Skip to content
Study details
Enrolling now

Do Endotypes Predict Response and Sequelae in OSA Patients

University of California, San Diego
NCT IDNCT04875364ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

200

Study length

about 6.4 years

Ages

21–65

Locations

1 site in CA

About this study

This trial is testing whether different underlying causes of Obstructive Sleep Apnea (OSA) predict how well people respond to treatment and what problems the disease might cause. The goal is to understand if knowing these 'endotypes' can help doctors choose the best way to treat each individual with OSA.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Supplemental Oxygen
  • 2.Take Eszopiclone
  • 3.Use Continuous Positive Airway Pressure (CPAP)
PhasePhase 2
DrugEszopiclone
Routeoral

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low15%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

eszopiclone, VARIOUS

Drug routes

oral (Oral Tablet)

Endpoints

Secondary: Brief Pain Inventory (Short Form), Diastolic Blood Pressure, Epworth Sleepiness Scale (ESS), Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-F), Insomnia Severity Index (ISI), PROMIS (Patient-Reported Outcomes Measurement Information System) pain intensity, PROMIS (Patient-Reported Outcomes Measurement Information System) pain interference, Pittsburgh Sleep Quality Index (PSQI)

Devices

therapeutic